Drug Profile
Research programme: hepatitis C and dengue virus therapeutics - Phynova
Alternative Names: PYN 18Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Phynova
- Class Antivirals; Herbal medicines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Dengue; Hepatitis C
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Hepatitis C in United Kingdom (unspecified route) (Botanic century pipeline, February 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Hepatitis-C in United Kingdom
- 28 Sep 2017 PYN 18 licensed to Botanic Century in China before September 2017 (Botanic Century pipeline, September 2017)